DTC whodunit: Rozerem ad gets rebuke

Share this article:
A sleep drug marketing mystery unfolded as Takeda and its agencies denied producing a TV ad that drew an FDA notice of violation.

FDA asked Takeda to stop running a 10-second Rozerem spot, which it said does not qualify as a reminder ad. The ad, advising viewers “Rozerem would like to remind you that it’s back to school time,” aired about four times in September on MSNBC.

“Our preliminary review of the situation indicates that no one internal to Takeda was involved in the approval, release or broadcast of the advertisement in question,” Matt Kuhn, Takeda director of PR, told MM&M. “We will continue to investigate how this happened and will include those findings in our response to the FDA.”

The ad cited was not part of the “Your dreams miss you” campaign, whose agencies, Cramer-Krasselt and AbelsonTaylor, told MM&M they did not create it. MSNBC could not be reached.

A source familiar with the situation speculated that the generic-looking spot may have been produced and aired by the cable network, with the brand name plugged in mistakenly as part of a larger ad placement deal. Calls to MSNBC were not returned.

FDA’s Division of Drug Marketing, Advertising and Communication interpreted the ad as being aimed at children, and noted that Rozerem is not indicated for pediatric use. DDMAC also cited Takeda for not submitting the ad to the agency, as required when ads are disseminated.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...